---
layout: default
title: Acetaldehyde Adenosine Triphosphate Disodium Allox
parent: 僅模型預測 (L5)
nav_order: 87
evidence_level: L5
indication_count: 0
---

# Acetaldehyde Adenosine Triphosphate Disodium Allox
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Formula: Evaluation Halted — Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This Evidence Pack describes a complex 30-ingredient multi-component preparation (including botanical extracts, insulin derivatives, vitamins, and homeopathic dilutions) with no confirmed single INN, no DrugBank ID, and no regulatory approval in the US market.
The TxGNN model returned **no predicted indications**, which is consistent with the pipeline's inability to map this heterogeneous mixture to a single DrugBank node.
With **0 clinical trials** and **0 publications** linked through the evidence pipeline, this candidate cannot proceed to standard repurposing evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no regulatory approval on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — no actual predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This submission contains **30 distinct active ingredients** rather than a single small-molecule drug. The list spans at least six fundamentally different pharmacological categories:

1. **Botanical/herbal extracts** — Berberis vulgaris root bark, Gymnema sylvestre leaf, Momordica balsamina immature fruit, Syzygium cumini seed, Trigonella foenum-graecum whole. Several of these are traditional anti-diabetic botanicals used in Ayurvedic and homeopathic systems.
2. **Insulin preparations** — Insulin Human and Insulin Pork, which are biologic peptides, not small molecules.
3. **Metabolic intermediates and organic acids** — Acetaldehyde, ATP disodium, fumaric acid, lactic acid, citric acid, phosphoric acid, phosphorus, NADIDE. These are endogenous biochemical substrates.
4. **Vitamins and cofactors** — Ascorbic acid, pantothenic acid, pyridoxine HCl, riboflavin, thiamine HCl, thioctic acid (alpha-lipoic acid).
5. **Hormonal/steroid compounds** — Prasterone (DHEA).
6. **Biological/homeopathic materials** — Human breast tumor cell, Salmonella enterica serovar Enteritidis, Sus scrofa pancreas, Lycopodium clavatum spore, pork liver, alloxan, phlorizin, barium oxalosuccinate.

The TxGNN knowledge graph operates on individual DrugBank-mapped single-entity drugs. Because this preparation has **no DrugBank ID** and cannot be resolved to a single molecular entity, the graph traversal finds no valid starting node and returns an empty prediction list. This is an expected pipeline behavior, not a data error.

---

## Safety Considerations

Please refer to the package insert for safety information.

> No drug interaction data was found in the DDI database for this multi-component formulation. Given the presence of **insulin preparations** and **biologically active botanicals** (e.g., Gymnema sylvestre, Trigonella foenum-graecum) that are known to affect blood glucose, clinically significant hypoglycemia risk should be assumed until a formal safety review is conducted.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This submission does not meet the minimum requirements for a TxGNN-based drug repurposing evaluation — it lacks a single resolvable drug entity, has no regulatory history, and the prediction pipeline returned no output. Proceeding without resolving the data gaps below would produce a report with no evidentiary basis.

**To proceed, the following is needed:**

- **Decompose the formulation**: Identify whether the submission is intended as a single homeopathic product (e.g., a specific brand with a known indication) or whether individual components should be evaluated separately.
- **Resolve the primary active ingredient**: If there is a single therapeutic principal (e.g., insulin, alpha-lipoic acid, berberine from Berberis vulgaris), isolate it and resubmit with its DrugBank ID for TxGNN analysis.
- **Obtain regulatory identity**: Retrieve the brand name, product registration number, and original approved indication from the relevant authority (TFDA, FDA, or homeopathic registry).
- **Obtain MOA data**: Without a DrugBank mapping, the mechanism of action cannot be automatically retrieved. Manual literature review is required.
- **Safety package**: Download the official package insert to complete the DG001 (key warnings/contraindications) and DG002 (MOA) data gaps flagged in the meta section.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

